Payment overview · 2025
General Payments
$437.87
17 reported records · 3 companies
Healthcare provider profile · identity verified
Tamara Jean Adams, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LEBANON, PA · NPI 1285626739
Verified facts
What the public records show
CMS Open Payments records show Tamara Jean Adams, M.D. received $437.87 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 45.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $200.83 | 45.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $169.80 | 38.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.24 | 15.4% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $437.87 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.33 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $169.80 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.80 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.23 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.31 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
150 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 701 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 162 |
| Omeprazole | Omeprazole | 575 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 127 |
| Lisinopril | Lisinopril | 478 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 347 | 95 |
| Simvastatin | Simvastatin | 319 | 82 |
| Losartan Potassium | Losartan Potassium | 317 | 94 |
| Lorazepam | Lorazepam | 296 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 85 |
| Gabapentin | Gabapentin | 276 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 63 |
| Eliquis | Apixaban | 233 | 43 |
| Furosemide | Furosemide | 199 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 63 |
| Sertraline Hcl | Sertraline Hcl | 184 | 47 |
| Metformin Hcl | Metformin Hcl | 174 | 49 |
| Atenolol | Atenolol | 157 | 38 |
| Alendronate Sodium | Alendronate Sodium | 152 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 35 |
| Synthroid | Levothyroxine Sodium | 150 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 39 |
| Tramadol Hcl | Tramadol Hcl | 144 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 36 |
| Famotidine | Famotidine | 114 | 34 |
| Bupropion Xl | Bupropion Hcl | 113 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 110 | 28 |
| Glipizide Er | Glipizide | 109 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 23 |
| Potassium Chloride | Potassium Chloride | 105 | 33 |
| Trazodone Hcl | Trazodone Hcl | 104 | 32 |
| Clonazepam | Clonazepam | 102 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 25 |
| Jardiance | Empagliflozin | 86 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 14 |
| Irbesartan | Irbesartan | 78 | 18 |
| Spironolactone | Spironolactone | 77 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 16 |
| Warfarin Sodium | Warfarin Sodium | 62 | 16 |
| Allopurinol | Allopurinol | 61 | 14 |
| Cephalexin | Cephalexin | 58 | 41 |
| Baclofen | Baclofen | 54 | 14 |
| Carvedilol | Carvedilol | 54 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 14 |
| Valsartan | Valsartan | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 52 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 40 |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Nystatin | Nystatin | 47 | 22 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Glipizide | Glipizide | 43 | 11 |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Alprazolam | Alprazolam | 40 | 16 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 14 |
| Amoxicillin | Amoxicillin | 32 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 13 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $437.87 · 17 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Ozempic, QULIPTA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error